Healthcare Practitioners

We are committed to providing healthcare professionals with the information and programs that will support their efforts to treat rare, monogenic diseases of the central nervous system.

Pipeline

25+ gene therapy candidates for CNS disorders

Partnerships

Foundational collaboration with UT Southwestern

Our Approach

Our gene therapy approach builds upon proven gene therapy platforms

Allying with Healthcare Professionals

Our Clinical Trials

Taysha is accelerating gene therapy research and clinical development across a broad range of monogenic CNS diseases. Clinical trials currently underway include:

For questions about Taysha programs and clinical trials please contact medinfo@tayshagtx.com

Medical Congresses and Events

Through participation in medical meetings and congresses, we seek to advance the understanding of disease and potential new treatment options. Explore our participation in these events here.

ASGCT 24th Annual Meeting

Pre-meeting workshops

Keynote Title: Attracting Capital and Building a Company in the Gene Therapy Space
Presenter: RA Session II, President, CEO and Founder, Taysha Gene Therapies
Session: Emerging Issues in Market Access Keynote Address

Panel Title: Working & Thriving in Industry – What You Need to Know to Prepare and Succeed
Presenter: Steven Gray, Ph.D., Associate Professor, UT Southwestern
Session: Transitioning from Academics to Industry Session

Panel Title: Learning from Experience – Case Studies of Transitions from Academia to Industry
Presenter: Fred Porter, Ph.D., Chief Technical Officer, Taysha Gene Therapies
Session: Transitioning from Academics to Industry

Panel Title: Understanding the Research Process: Being Equipped for Success
Presenter: Steven Gray, Ph.D., Associate Professor, UT Southwestern
Session: Patient Advocates’ Role in Advancing Gene Therapy

17th Annual WorldSymposium 2021

Virtual Poster Presentation

Title: Co-creating a gene therapy clinical trial with GM2 gangliosidosis caregivers: A Virtual approach to patient engagement
Presenter: Kristin LaBounty Phillips, Senior Director, Community Engagement, Taysha Gene Therapies

ASGCT 23rd Annual Meeting 2020

Oral Presentations

Title: A New Approach for Designing a Feedback-Enabled AAV Genome Improves Therapeutic Outcomes of MiniMeCP2 Gene Transfer in Mice Modeling Rett Syndrome (RTT)
Presenter: Sarah E. Sinnett, Ph.D., Assistant Professor, Pediatrics, UT Southwestern Medical Center
Session: AAV Gene Delivery for CNS Disorders

Title: Intrathecal Delivery of Human Bicistronic Hexosaminidase Vector (TGTX-101) to Correct Sandhoff Disease in a Murine Model: A Dosage Study
Presenter: Alex E. Ryckman, Centre for Neuroscience Studies, Queen’s University
Session: Main session, AAV Gene Delivery for CNS Disorders

Title: Direct Vagus Nerve Injection of AAV9 as a Treatment Approach for Autonomic Dysfunction in Giant Axonal Neuropathy
Presenter: Rachel M. Bailey, Ph.D., Assistant Professor, Neuroscience, UT Southwestern Medical Center
Session: New Techniques in Gene Therapy for Neurological Disorders

Poster Presentations

Title: SMRT Sequencing Allows High-Throughput Analysis of a Whole Capsid Shuffled AAV Capsid Library Following CNS Selection in Mice and NHPs
Presenter: Widler Casy, Ph.D., Postdoctoral Researcher, UT Southwestern Medical Center
Session: AAV Vectors – Virology and Vectorology

Title: Gene Replacement Therapy for SURF1-Related Leigh Syndrome Using AAV9
Presenter: Qinglan Ling, Ph.D., Postdoctoral Researcher, UT Southwestern Medical Center
Session: Neurologic Diseases

Title: A Dosage Study to Assess the Long-Term Effects of Gene Therapy for AB-Variant GM2 Gangliosidoses in a Mouse Model Using Adeno-Associated Virus Serotype 9
Presenter: Natalie M. Deschenes, Centre for Neuroscience Studies, Queen’s University
Session: Main Session: Neurologic Diseases

Title: Preclinical Safety and Efficacy of AAV9 Gene Replacement Therapy for SLC6A1 Disorder
Presenter: Frances Shaffo, Ph.D., Postdoctoral Researcher, UT Southwestern Medical Center
Session: Neurologic Diseases

Taysha is a Rare Ally

Learn more about our commitment to patients and caregivers living with rare monogenic CNS disease.

Expanded Access Policy

Expanded Access, sometimes called Managed Access, Compassionate Use or Early Access, is a potential pathway for a patient with an immediately life-threatening condition, serious disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

At Taysha, we are collaborating closely with patients, caregivers, patient organizations and medical experts to conduct safe and effective clinical trials.  We believe participation in well-designed clinical trials is the most ethical way to determine the safety and efficacy of investigational therapies. Clinical experience from well-controlled trials provide the highest probability of success of bringing an approved therapy to the entire patient community in a safe manner.  Hence, Taysha does not offer an Expanded Access Program anywhere in the world.

If you have questions about participating in our clinical trials, please discuss with your health care provider, or contact us at: medinfo@tayshagtx.com.

We reserve the right to revise this policy at any time in accordance with the 21st Century Cures Act.

References

  1. FDA Guidance for the Industry: Expanded Access to Investigational Drugs for Treatment Use — Questions and Answers. Updated 2017
  2. Jarrow et al: Overview of FDA’s Expanded Access Program for Investigational Drugs. Ther Innov Regul Sci. 2017 March 1; 51(2): 177–179. doi:10.1177/2168479017694850.
  3. 21st Century Cures Act

For questions about programs and clinical trials please contact medinfo@tayshagtx.com.